Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product ...

Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical ...

The transaction between Thermo Fisher and Sanofi is scheduled for completion in Q2 2025, subject to standard closing ...

Thermo Fisher is acquiring Sanofi’s Ridgefield, NJ sterile drug plant, transferring 200 employees to bolster U.S. fill‑finish ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Under the expanded partnership, Thermo Fisher will acquire Sanofi's sterile fill-finish and packaging facility in Ridgefield, N.J. The science-services and instruments provider said Wednesday that it ...

Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

In a move to bolster its drug manufacturing capabilities in the United States, Thermo Fisher has purchased a sterile fill-finish and packaging plant from Sanofi in Ridgefield, New Jersey.

Thermo Fisher Scientific Inc. has expanded its strategic partnership with Sanofi to enable additional U.S. drug product manufacturing.

Thermo Fisher (TMO) stock slips as plant producing RSV treatment. Beyfortus developed by AstraZeneca (AZN), Sanofi (SNY) fails FDA quality standards. Read more here.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Thermo Fisher (TMO – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments.

But Thermo Fisher’s latest expansion is just one of many in Singapore from industry giants. Just last year, Merck & Co., Sanofi, WuXi Biologics and GSK either announced plans to build new plants ...